Pancreatic Cancer Research

Clinical trialPhase 1Not yet recruiting

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

A Phase 1b, Dose-Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients With Relapsed or Refractory Solid Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Start
August 2023
Expected end
February 2027
Enrollment
36 participants
Sites
0
Primary outcomes
Incidence of adverse events (AEs); Incidence of immune-related adverse events (IrAEs)
Sponsor type
Industry
Results posted
No
Last update
12 April 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).

Detailed description public domain (ClinicalTrials.gov)

This is a Phase 1b, dose-ascending study to assess the safety, tolerability and recommended phase 2 dose (RP2D) of STI-1386 in subjects with relapsed and refractory solid tumors (RRSTs). STI-1386 is a second generation oncolytic virus. This is a two-stage study, the first stage uses a single ascending dose, followed by the multiple ascending dose stage.